Rigel entered into an exclusive license and supply agreement with Knight in May 2022, to commercialize fostamatinib disodium hexahydrate (fostamatinib) in all potential indications in Latin America.
As of February 2024, Knight had submitted marketing authorization applications for fostamatinib in Brazil, Colombia and Mexico.
Rigel received an upfront cash payment, with the potential for additional regulatory and commercial milestones, and stepped-up royalties based on tiered net sales.